Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Alkermes plc ALKS
$31.13
-$0.05 (-0.17%)
На 18:00, 12 мая 2023
-2.57%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
5183805555.00000000
-
week52high
32.23
-
week52low
21.75
-
Revenue
1111795000
-
P/E TTM
-27
-
Beta
0.61038000
-
EPS
-0.99000000
-
Last Dividend
0.00000000
-
Next Earnings Date
26 апр 2023 г. в 12:00
Описание компании
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Neutral | 16 авг 2022 г. | |
| Mizuho | Buy | Buy | 28 июл 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 28 апр 2022 г. |
| HC Wainwright & Co. | Neutral | Neutral | 28 апр 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 21 апр 2022 г. |
| B of A Securities | Neutral | Underperform | 14 окт 2022 г. |
| Piper Sandler | Overweight | Neutral | 03 ноя 2022 г. |
| Mizuho | Buy | Buy | 22 ноя 2022 г. |
| JP Morgan | Neutral | Neutral | 06 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| LAURENCIN CATO T | D | 8163 | 4082 | 08 дек 2022 г. |
| LAURENCIN CATO T | D | 0 | 4160 | 08 дек 2022 г. |
| LAURENCIN CATO T | D | 7479 | 378 | 08 дек 2022 г. |
| LAURENCIN CATO T | A | 7857 | 4082 | 08 дек 2022 г. |
| LAURENCIN CATO T | D | 3775 | 385 | 08 дек 2022 г. |
| LAURENCIN CATO T | A | 4160 | 4160 | 08 дек 2022 г. |
| Daglio David Angelo Jr. | A | 80000 | 35000 | 14 ноя 2022 г. |
| Gaffin David Joseph | A | 7899 | 7899 | 03 авг 2022 г. |
| Gaffin David Joseph | A | 28812 | 28812 | 03 авг 2022 г. |
| Wysenski Nancy | A | 11554 | 11554 | 07 июл 2022 г. |
Новостная лента
Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates
Zacks Investment Research
27 апр 2023 г. в 10:38
Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research
26 апр 2023 г. в 10:40
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alkermes (ALKS) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research
26 апр 2023 г. в 09:54
Alkermes (ALKS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.12 per share a year ago.
Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why
Zacks Investment Research
15 мар 2023 г. в 13:45
Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.
Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up
Zacks Investment Research
17 февр 2023 г. в 13:33
Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.